Emre ÖZER, Nilay GÜNEŞ, Beyhan TÜYSÜZ, Olcay EVLİYAOĞLU, Birsen KARAMAN

A rare intrauterine onset growth retardation syndrome caused by mosaic 19p13.3 microduplication: evaluation of GH/IGF- 1 axis and GH therapy response

Background. 19p13.3 microduplication syndrome is a newly defined intrauterine onset growth retardation syndrome characterized by microcephaly, moderate intellectual disability, speech delay, and mild dysmorphic features. The PIAS4 gene located in this region plays a crucial role as a transcriptional co-regulator in various cellular pathways including STAT, p53/TP53 and growth hormone (GH) signaling and mutations in this gene are thought to be responsible for clinical features. Case. We present a 10 year-old girl with intrauterine onset growth retardation, microcephaly, and mild facial dysmorphic features. Treatment with GH was started at 4 years and 9 months of age targeting the severe short stature (-3.65 standard deviation score, SDS) since she had significant IGF-1 response to exogenous GH. Microarray study demonstrated a 19p13.3 microduplication of 4.4 Mb. FISH analyses revealed mosaic extra signals (27.5% on blood lymphocytes, and 47% on buccal epithelium) of 19p13.3 region. At the age of 10, her height was at -2.37 SDS, and she had mild intellectual disability which has been described in 19p13.3 microduplication syndrome. Conclusion. We present here a patient with typical findings of 19p13.3 microduplication syndrome and also with a prominent response to GH treatment, which has not been reported previously in this syndrome.

PDF

___

1. Nevado J, Rosenfeld JA, Mena R, et al. PIAS4 is associated with macro/microcephaly in the novel interstitial 19p13.3 microdeletion/microduplication syndrome. Eur J Hum Genet 2015; 23: 1615-1626.

2. Ishikawa A, Enomoto K, Tominaga M, et al. Pure duplication of 19p13.3. Am J Med Genet A 2013; 161A: 2300-2304.

3. Siggberg L, Olsén P, Näntö-Salonen K, Knuutila S.19p13.3 aberrations are associated with dysmorphic features and deviant psychomotor development. Cytogenet Genome Res 2011; 132: 8-15.

4. Orellana C, Roselló M, Monfort S, Mayo S, Oltra S, Martínez F. Pure duplication of 19p13.3 in three members of a family with intellectual disability and literature review. Definition of a new microduplication syndrome. Am J Med Genet A 2015; 167: 1614-1620.

5. Novikova I, Sen P, Manzardo A, Butler M G. Duplication of 19p13.3 in 11-year-old male patient with dysmorphic features and intellectual disability: a review. J Pediatr Genet 2017; 6: 227-233.

6. Tenorio J, Nevado J, González-Meneses A, et al. Further definition of the proximal 19p13.3 microdeletion/microduplication syndrome and implication of PIAS4 as the major contributor. Clin Genet 2020; 97: 467-476.

7. Andries S, Sartenaer D, Rack K, et al. Pure terminal duplication of the short arm of chromosome 19 in a boy with mild microcephaly. J Med Genet 2002; 39: E60.

8. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010; 11: 861-871.

9. Ihara M, Yamamoto H, Kikuchi A. SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol Cell Biol 2005; 25: 3506-3518.

10. Kumar R, Cheok CF. Dynamics of RIF1 SUMOylation is regulated by PIAS4 in the maintenance of Genomic Stability. Sci Rep 2017; 7: 17367.

11. Xiong R, Nie L, Xiang L, Shao JZ. Characterization of a PIAS4 homologue from zebrafish:insights into its conserved negative regulatory mechanism in the TRIF, MAVS, and IFN signaling pathways during vertebrate evolution. J Immunol 2012; 188: 2653- 2668.

12. Burn B, Brown S, Chang C. Regulation of early Xenopus development by the PIAS genes. Dev Dyn 2011; 240: 2120-2126.

13. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3- ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009; 462: 935-939.

14. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet 2013; 14: 307-320